<DOC>
	<DOCNO>NCT00876070</DOCNO>
	<brief_summary>This retrospective medical record abstraction study . It review evaluation 300 metastatic breast cancer patient treat Abraxane taxanes paclitaxel docetaxel determine overall cost care Abraxane compare taxanes first-line metastatic cancer set cost care Abraxane compare taxanes break individual component cost . In addition , investigator review follow patient outcome : response rate , duration therapy , toxicity , survival .</brief_summary>
	<brief_title>Community Oncology Setting Cost Analysis Disease Outcomes Taxane Use Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Patients receive Abraxane chemotherapy great three month time chart review . Patients receive taxane chemotherapy great three month time chart review .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>MBC</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Taxotere</keyword>
</DOC>